Sugi Predict

Sugi Predict / Compounds / SCHEMBL476844

SCHEMBL476844

SCHEMBL476844

CC(=O)c1ccc(B2OC(C)(C)C(C)(C)O2)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LPL P06858 11/20 0.52
▸ LIPG Q9Y5X9 11/20 0.52
▸ P4HB P07237 1/20 0.51
▸ CA1 P00915 6/20 0.50
▸ CA2 P00918 6/20 0.50
▸ CA9 Q16790 6/20 0.50
▸ CA12 O43570 1/20 0.47
▸ CA3 P07451 1/20 0.47
▸ CA4 P22748 1/20 0.47
▸ CA6 P23280 1/20 0.47
▸ CA5A P35218 1/20 0.47
▸ CA7 P43166 1/20 0.47
▸ CA14 Q9ULX7 1/20 0.47
▸ CA5B Q9Y2D0 1/20 0.47
▸ F11 P03951 2/20 0.47
▸ F2 P00734 1/20 0.47
▸ PRSS1 P07477 1/20 0.47
▸ PRSS2 P07478 1/20 0.47
▸ PRSS3 P35030 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5899476 0.95 LIPG (0.61) LPLLIPGP4HBCA1CA2
SCHEMBL14782605 0.90 MAPT (0.59) LPLLIPGP4HBCA1CA2
SCHEMBL21797212 0.89 P4HB (0.57) LPLLIPGP4HBCA1CA2
SCHEMBL21797213 0.89 P4HB (0.57) LPLLIPGP4HBCA1CA2
SCHEMBL14942938 0.87 CA1 (0.57) CA1CA2CA9CA12CA3
SCHEMBL18870485 0.87 P4HB (0.42) LPLLIPGP4HBCA1CA2
SCHEMBL3760918 0.86 LPL (0.53) LPLLIPGP4HBCA1CA2
SCHEMBL26831135 0.86 LPL (0.53) LPLLIPGP4HBCA1CA2
SCHEMBL18870482 0.85 LIPG (0.44) LPLLIPGP4HBCA1CA2
SCHEMBL105188 0.85 LIPG (0.56) LPLLIPGP4HBCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113956274-A Design and synthesis method of fluorescent probe capable of responding to viscosity and peroxynitrite change in epileptic diseases 南京碳硅人工智能生物医药技术研究院有限公司 2022-01-21 — — CN claimed
US-20260050210-A1 RESIST COMPOSITION AND METHOD FOR PRODUCING SAME NIPPON SHOKUBAI CO., LTD. (JP) 2026-02-19 — — US disclosed
US-20250282787-A1 SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS Mirati Therapeutics, Inc. 2025-09-11 — — US disclosed
US-12371435-B2 Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors Mirati Therapeutics, Inc. (US) 2025-07-29 — — US disclosed
CN-119684586-A Polyether base oil and preparation method thereof 万华化学集团股份有限公司 2025-03-25 — — CN disclosed
WO-2025043191-A1 PRC2 INHIBITORS FOR USE IN TREATING SICKLE CELL DISEASE ORIC PHARMACEUTICALS, INC. (US) 2025-02-27 — — WO disclosed
EP-3240543-B1 BTK INHIBITORS MERCK SHARP & DOHME LLC (US) 2024-11-06 — — EP disclosed
US-20240360082-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2024-10-31 — — US disclosed
EP-4043466-B1 PRC2 INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-08-21 — — EP disclosed
WO-2024122460-A1 RESIST COMPOSITION AND METHOD FOR PRODUCING SAME 株式会社日本触媒 2024-06-13 — — WO disclosed
WO-2011059887-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-05-19 — — WO disclosed
WO-2011059850-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-05-19 — — WO disclosed
WO-2010110782-A1 METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-09-30 — — WO disclosed
US-20100081643-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS MERCK SHARP & DOHME LLC 2010-04-01 — — US disclosed
WO-2010036613-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS MERCK SHARP & DOHME CORP. (US) 2010-04-01 — — WO disclosed
US-20090134384-A1 ORGANIC ELECTROLUMINESCENT DEVICE AND BORIC ACID AND BORINIC ACID DERIVATIVES USED THEREIN MERCK PATENT GMBH (DE) 2009-05-28 — — US disclosed
EP-1888706-A1 ORGANIC ELECTROLUMINESCENT DEVICE AND BORIC ACID AND BORINIC ACID DERIVATIVES USED THEREIN Merck Patent GmbH (DE) 2008-02-20 — — EP disclosed
EP-1663936-B1 BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS HOFFMANN LA ROCHE (CH) 2008-01-09 — — EP disclosed
EP-1183232-B1 MONOFLUOROALKYL DERIVATIVES LILLY CO ELI (US) 2007-10-03 — — EP disclosed
WO-2006117052-A1 ORGANIC ELECTROLUMINESCENT DEVICE AND BORIC ACID AND BORINIC ACID DERIVATIVES USED THEREIN MERCK PATENT GMBH (DE) 2006-11-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090134384-A1 ORGANIC ELECTROLUMINESCENT DEVICE AND BORIC ACID AND BORINIC ACID DERIVATIVES USED THEREIN BTD, ERG, OR10J3 LPL 4156/4885LIPG 2769/4885P4HB 3871/4885
US-12371435-B2 Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors EZH2, BMI1, SUZ12 LPL 4722/4885LIPG 4148/4885P4HB 3376/4885
US-20100081643-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS PRKAG2, PRKAG1, PRKAB2 LPL 402/4885LIPG 287/4885P4HB 4230/4885
US-20250282787-A1 SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS EZH2, BMI1, SUZ12 LPL 3655/4885LIPG 3459/4885P4HB 4310/4885
US-20260050210-A1 RESIST COMPOSITION AND METHOD FOR PRODUCING SAME MAL2, MCM6, MCM3 LPL 2899/4885LIPG 2909/4885P4HB 3995/4885
US-20240360082-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS PNPO, PDXK, PLPBP LPL 1994/4885LIPG 2161/4885P4HB 619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.